Pathology of Triple-Negative Breast Cancer: Clinical Implications and Therapeutic Strategies

Triple-negative breast cancer (TNBC) represents a unique subtype characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. This track will delve into the intricate pathology of TNBC, exploring its clinical implications and therapeutic strategies. Attendees will gain insights into the aggressive nature of TNBC, its distinct molecular features, and the challenges associated with diagnosis and treatment. Discussion will focus on emerging biomarkers, novel targeted therapies, and immunotherapy approaches. By understanding the underlying pathology of TNBC, participants will be equipped to optimize patient management, improve prognostic evaluation, and contribute to the development of personalized therapeutic interventions.

  • Molecular Subtypes and Biomarkers in Triple-Negative Breast Cancer
  • Therapeutic Strategies and Future Directions for Triple-Negative Breast Cancer

Related Conference of Pathology of Triple-Negative Breast Cancer: Clinical Implications and Therapeutic Strategies

March 10-11, 2025

3rd World Congress on Oral Cancer

Paris, France
March 24-25, 2025

25th World Congress on Cancer and Diagnostics

London, UK
March 24-25, 2025

10th World Conference on Breast and Cervical Cancer

Paris, France
April 07-08, 2025

15th World Congress on Breast Cancer

Vancouver, Canada
April 28-29, 2025

35th Experts Meet On Cancer Research & Therapy

Aix-en-Provence, France
June 16-17, 2025

26th World Congress on Cancer Summit

Amsterdam, Netherlands
July 14-15, 2025

5th World Congress on Breast Cancer

Berlin, Germany
July 28-29, 2025

45th Euro Congress on Cancer Science & Therapy

Aix-en-Provence, France
October 20-21, 2025

21st International Conference on Cancer Research

Barcelona, Spain

Pathology of Triple-Negative Breast Cancer: Clinical Implications and Therapeutic Strategies Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in